
Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
ORXOY | OTC Markets | USD | Delayed | |
ORX | Stockholm | SEK | Real-time |
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
Name | Age | Since | Title |
---|---|---|---|
Robin Evers | 54 | 2023 | Independent Director |
Christine Rankin | 61 | 2022 | Independent Director |
Staffan Lindstrand | 63 | 2002 | Independent Director |
Frederick George Wilkinson | 69 | 2019 | Independent Director |
Friedrich von bohlen Und halbach | 63 | 2024 | Independent Chairman |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review